Vertex Secures Hat Trick Of Europe CF Approvals With Nod For Symkevi
Now that the EMA has followed its US counterpart in granting approval for its cystic fibrosis drug Symkevi, Vertex will once again have to navigate Europe's various reimbursement systems, with observers keeping a close eye on how talks with NICE go.
You may also be interested in...
Vertex duplicated promising efficacy observed in Phase II for its cystic fibrosis triple combo that includes VX-659, but wants to see data expected in early 2019 for a triplet containing VX-445 before filing for approvals.
Infographic: Vertex, the first company to produce a drug to treat the underlying cause of cystic fibrosis, has fought for fair (and high) prices for its medicines to reflect their value as treatments for the cause of a genetic disease. The company has sought innovative reimbursement agreements for its CF products in various countries.
Vertex is set to reap huge benefits from its triple combination program for cystic fibrosis over the next 10 years, potentially becoming the biggest selling drug in this disease, according to a new report from Datamonitor Healthcare.